T cell-based cancer immunotherapy depends on the ability of blood-borne T cells to gain access to malignant tissues in order to initiate tumor-target destruction. While expansion of the pool of circulating effector T cells can be achieved therapeutically by adoptive T cell transfer, the overall success of immunotherapy strategies has been limited. Our studies have defined a paucity of trafficking molecules on tumor microvessels that are required for T cell entry into the tumor microenvironment. However, we have discovered that the tumor microenvironment can be exploited favorably by systemic thermal therapy (STT) to increase the adhesive properties of vascular endothelial cells that serve as gateways to tumor tissues. These observations lead us to hypothesize that systemic thermal therapy (STT) can improve the efficacy of adoptive T cell therapy by targeting the delivery of cytolytic T lymphocytes to primary and metastatic sites of tumor growth. The proposed studies are formulated on the basis of the identification of a novel lymphocyte-endothelial-interleukin-6 (IL-6) axis in murine tumor models that mediates the proadhesive activities of STT. A major adhesive target of STT is the vascular gatekeeper, intercellular adhesion molecule-1 (ICAM-1), which supports both firm arrest of T cells on vessel walls and transendothelial migration.
In Aim 1 we plan to build on our previous findings to determine if STT acts through an IL-6-dependent mechanism to modify additional trafficking molecules (adhesion receptors, chemokines) that recruit T cells in a murine B16 melanoma model of adoptive immunotherapy. Complementary in situ imaging studies will investigate the contribution of endogenous human IL-6 in mobilizing adoptively transferred T cells in a preclinical xenograft model of human melanoma.
In Aim 2 We will test the hypothesis that preconditioning of the host tissue environment by transient lymphodepletion amplifies the effects of STT on the trafficking of effector T cells to murine melanoma tumor tissues. The combinatorial effects of this multimodality therapy on ICAM-1-dependent entry of CD8 effector T cells in tumor tissues will be defined using antibody-blocking strategies and adhesion-deficient mice. A causal relationship between early T cell entry into tumor tissues and tumor cell apoptosis will be evaluated.
Aim 3 will test the hypothesis that enhancement of the local chemokine availability on the tumor vascular landscape can collaborate with STT to enhance CD8 T cell trafficking to tumor tissues during adoptive transfer. The requirement for the chemokine/chemokine receptor pair, CXCL10/CXCR3, in mediating the transition of T cells from initial rolling interactions to ICAM-1-dependent firm arrest in tumor vessels will be probed using a sustained-release microsphere system for delivery of CXCL10. The proposed studies are expected to provide new insights into mechanisms of T cell delivery to the tumor microenvironment and offer a conceptual basis for novel therapeutic strategies in cancer immunotherapy.

Public Health Relevance

Despite considerable progress in the development of immunotherapy strategies in cancer, these therapies have had minimal overall impact and treatment options continue to be limited for advanced-stage patients. This proposal is formulated based on our findings that systemic thermal therapy is a novel approach to target the delivery of tumor-specific cytolytic T lymphocytes to the tumor microenvironment, thereby overcoming a significant barrier to T cell-based immunotherapy. The proposed studies are expected to provide needed insights into the dynamic mechanisms that underlie targeted delivery of effector T cells to the tumor microenvironment and offer a conceptual basis for novel therapeutic strategies in cancer immunotherapy.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Radiation Therapeutics and Biology Study Section (RTB)
Program Officer
Wong, Rosemary S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Roswell Park Cancer Institute Corp
United States
Zip Code
Ito, Fumito; Evans, Sharon S (2016) Pre-resectional Radiofrequency Ablation as a Neoadjuvant in situ Tumor Vaccine. J Vaccines Vaccin 7:
Mikucki, Maryann E; Skitzki, Joseph J; Frelinger, John G et al. (2016) Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy. Oncoimmunology 5:e1116675
Fisher, Daniel T; Muhitch, Jason B; Kim, Minhyung et al. (2016) Intraoperative intravital microscopy permits the study of human tumour vessels. Nat Commun 7:10684
Ku, Amy W; Muhitch, Jason B; Powers, Colin A et al. (2016) Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes. Elife 5:
Evans, Sharon S; Repasky, Elizabeth A; Fisher, Daniel T (2015) Fever and the thermal regulation of immunity: the immune system feels the heat. Nat Rev Immunol 15:335-49
Mikucki, M E; Fisher, D T; Matsuzaki, J et al. (2015) Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun 6:7458
Ito, Fumito; Ku, Amy W; Bucsek, Mark J et al. (2015) Immune Adjuvant Activity of Pre-Resectional Radiofrequency Ablation Protects against Local and Systemic Recurrence in Aggressive Murine Colorectal Cancer. PLoS One 10:e0143370
Fisher, Daniel T; Appenheimer, Michelle M; Evans, Sharon S (2014) The two faces of IL-6 in the tumor microenvironment. Semin Immunol 26:38-47
Brackett, Craig M; Muhitch, Jason B; Evans, Sharon S et al. (2013) IL-17 promotes neutrophil entry into tumor-draining lymph nodes following induction of sterile inflammation. J Immunol 191:4348-57
Mikucki, Maryann E; Fisher, Daniel T; Ku, Amy W et al. (2013) Preconditioning thermal therapy: flipping the switch on IL-6 for anti-tumour immunity. Int J Hyperthermia 29:464-73

Showing the most recent 10 out of 32 publications